Cellectis S.A. (NASDAQ: CLLS)

This investigation is for anyone who acquired securities in Cellectis S.A. (NASDAQ: CLLS) prior to September 14, 2026.

The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by telling investors that the Company had sufficient financing to continue the development of the Company’s CAR-T cell therapies lasme-cel and eti-cel when the Company lacked such financing.

On September 14, 2026, Cellectis announced it would prioritize in vivo gene editing therapies (HEAL-101 and HEAL-201) over CAR-T cell therapies. The Company concurrently announced it plans to discontinue the development of CAR-T cell therapies lasme-cel and eti-cel. In the accompanying conference call, the Company’s Chief Medical Officer, Adrian Kilcoyne stated “Cellectis is not able finance [Eti-cel and Lasme-cel] given the time lines that we have and the limited cash resources that we have.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Cellectis S.A. (NASDAQ: CLLS) prior to September 14, 2026 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.